Amicus Therapeutics (FOLD) Stock Forecast & Price Target

Amicus Therapeutics Inc. has demonstrated a robust performance with Galafold achieving approximately 18% year-over-year sales growth in fiscal year 2024, resulting in total sales of $458 million, alongside the largest increase in new patient demand since its launch. The company anticipates continued momentum, expecting Galafold sales to grow by 10-15% on a constant exchange rate basis in 2025, aligning with an estimated $504 million in sales for that year. Furthermore, Amicus is gaining significant market share in the Pompe disease segment, aided by stronger-than-expected sales for its pom/opf product, which, combined with advancements in patient identification through AI initiatives, positions the company favorably for future growth in the rare disease treatment market.

The financial outlook for Amicus Therapeutics is negatively influenced by several key metrics and market dynamics. Although Galafold sales for FY:24 showed an 18% year-over-year growth, the forecast for FY:25 predicts a potential revenue decline as the treatment's patient pool diminishes, with total revenues expected to fall by $5M to $15M due to exchange rate impacts. Additionally, lowered sales estimates for the Pompe disease treatment, now projected at $126M instead of the previously estimated $139M, coupled with the possibility of delays caused by increased regulatory requirements from the FDA, further exacerbate the company's uncertain financial trajectory.